PMA eSTAR: What FDA's New Electronic Submission Draft Means for Canadian Class III Device Makers

For a Canadian company taking a Class III device into the United States, the Premarket Approval application is the most demanding submission in the FDA system. It carries the highest evidentiary bar, the longest review, and the least tolerance for a disorganised dossier. On 18 September 2026, FDA signalled that the way this submission is assembled is about to change. The agency published draft guidance introducing the electronic Submission Template and Resource, known as eSTAR, for Premarket Approval Applications and their supplements.

eSTAR is already the mandatory route for 510(k) and De Novo submissions. Extending its guided, structured model to PMAs points to a future where a free-form technical dossier gives way to a validation-gated template that will not submit unless it is complete. For Canadian manufacturers, that turns content gaps which review once absorbed into upfront blockers. This guide explains what FDA announced, what the PMA eSTAR is, why it matters for Canadian Class III device makers, and what to do before the comment window closes on 17 November 2026.

Executive summary

FDA has issued draft guidance titled Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs), announced in the Federal Register on 18 September 2026 under docket FDA-2026-D-9429, with comments due by 17 November 2026. The guidance introduces the publicly available resources that support electronic submission of certain PMAs and PMA supplements to the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research. Use of eSTAR for PMAs is voluntary today, but the direction of travel is clear from the 510(k) and De Novo experience, where the template is mandatory. Canadian Class III device makers should begin mapping their technical file content to eSTAR fields now, rather than waiting for a final rule.

What FDA announced, in plain terms

What it is. FDA announced the availability of a draft guidance for industry and FDA staff titled Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs). The Federal Register notice introduces submitters to the current publicly available resources and associated content developed to support electronic submission of certain PMAs and PMA supplements to FDA.

Why it matters. When finalised, the guidance represents one of several steps in FDA's commitment to electronic submission templates that serve as guided preparation tools, improving submission consistency and review efficiency. In practice, it moves the PMA toward the same structured model already used for lower-risk devices, which is a meaningful shift for the most complex submission type in the system.

What to do. Read the draft against your own PMA content, and if the template would create difficulties for your device type, submit a comment before 17 November 2026 so the agency can consider it before the final version. The key facts are summarised below.

What eSTAR is and why it matters for PMAs

Direct answer. eSTAR is an interactive PDF form that guides applicants through the preparation of a comprehensive medical device submission. It shows only the sections relevant to your device based on your answers, builds in forms such as the Indications for Use and the cover sheet, and will not report itself complete until every required element is present. For a PMA, that structure replaces a loosely assembled dossier with a template that enforces completeness before you can submit.

The completeness discipline has a direct review consequence. Because a properly prepared eSTAR should represent a complete submission, eSTAR submissions are not anticipated to undergo the Refuse to Accept process. FDA instead applies virus scanning and a technical screening. If an eSTAR fails technical screening, for example because the attachments for a question are not relevant to it, the submission may be placed on a technical screening hold for up to 180 days, and if no replacement is received within that window the submission is considered withdrawn. The template rewards accuracy and penalises gaps, which is precisely why the content mapping must happen before you start filling it in.

Mandatory today for some submissions, voluntary for PMAs

Per the FDA eSTAR Program page, eSTAR is mandatory for all 510(k) and De Novo submissions to CDRH or CBER unless exempted, including combination product 510(k) and De Novo submissions and dual 510(k) and CLIA Waiver in vitro diagnostic submissions. Use of eSTAR for PMAs and their supplements, for Q-Submissions, for Investigational Device Exemptions and for 513(g) requests is currently voluntary. The current nIVD and IVD eSTAR templates already accommodate PMA submissions, so the tooling exists ahead of any mandate.

Why this matters for Canadian Class III device makers

Direct answer. In the United States, most Class III devices reach the market through the Premarket Approval pathway, which requires valid scientific evidence of safety and effectiveness. A Canadian manufacturer that has cleared a device in Canada cannot simply carry that file across the border. The eSTAR template makes the gap between a Canadian technical file and a US PMA explicit, because each field must be answered and each expected attachment must be present.

The practical effect is that content weaknesses surface earlier. Under a free-form dossier, a thin biocompatibility rationale or an incomplete software file might be raised as a deficiency during review. Inside eSTAR, the absence of that content can prevent the template from reaching a complete status or can trigger a technical screening hold. Manufacturers that have already aligned their quality system to the FDA Quality Management System Regulation and ISO 13485 will find the transition easier, because the underlying records the template asks for already exist.

Two adjacent points matter for Canadian firms. First, the eSTAR templates now incorporate current human factors content, so the human factors submission categories you select feed directly into what the template asks for. Second, PMA user fees are significant, and a Canadian firm may qualify for a reduced fee, as we explain in our guide to the FDA small business discount Canadian device firms miss. Getting the fee status and the submission structure right at the same time avoids paying twice for one lesson.

How to get ready now

Direct answer. The work that pays off before eSTAR becomes routine for PMAs is a content mapping exercise: take the eSTAR structure and map each section to where that content lives in your current technical file, then close the gaps. Do this before you attempt to populate the template, not during.

• Run a PMA readiness gap assessment. Map device description, indications, non-clinical and clinical evidence, biocompatibility, software, sterilisation and labelling to the eSTAR sections and record what is missing.
• Confirm your fee status. Establish whether your firm qualifies for the FDA small business fee reduction well before you plan to submit, since the certification has its own lead time.
• Standardise your attachments. Adopt clear, consistent file naming and combine related documents, because eSTAR organises the submission by attachment and rewards a tidy structure.
• Comment before 17 November 2026. If the template creates a genuine difficulty for your device type, submit a comment to docket FDA-2026-D-9429 so the agency can consider it before finalising.

Common mistakes

• Waiting for a mandate. Treating the voluntary status as a reason to delay. The 510(k) and De Novo history shows the direction of travel, and early mapping is cheaper than a rushed transition.
• Assuming a Canadian file transfers. Expecting a Health Canada licence file to satisfy a US PMA. The evidence expectations and the structure differ, and eSTAR makes the differences visible.
• Populating before mapping. Opening the template and filling it in without first mapping content, which surfaces gaps at the worst possible moment.
• Inaccurate template answers. Giving inaccurate responses to dropdown fields, which can cause the template to omit later questions and can lead to an early hold in the review.

PMA eSTAR readiness checklist

• You have mapped every eSTAR section to a location in your current technical file.
• Content gaps in evidence, biocompatibility, software and sterilisation are logged with owners and dates.
• Your quality system records align with the FDA QMSR and ISO 13485 expectations the template draws on.
• Human factors content and categories are prepared to match what the template asks for.
• Your small business fee status is confirmed, or the certification is in progress.
• Attachment naming and combination follow a consistent, reviewer-friendly convention.
• A decision has been made on whether to comment on the draft before 17 November 2026.

Frequently asked questions

What is PMA eSTAR?

PMA eSTAR is the use of FDA's electronic Submission Template and Resource, an interactive PDF form, to prepare a Premarket Approval application. FDA published draft guidance on 18 September 2026 introducing the resources that support electronic submission of certain PMAs and PMA supplements to CDRH and CBER.

Is eSTAR mandatory for PMAs?

Not yet. Use of eSTAR for PMAs and their supplements is currently voluntary. eSTAR is mandatory for 510(k) and De Novo submissions unless exempted. The draft guidance is a step toward a guided electronic submission model for PMAs.

When is the comment deadline?

Comments on the draft guidance are due by 17 November 2026, to docket FDA-2026-D-9429, so that FDA can consider them before beginning work on the final version.

What happens if an eSTAR is incomplete?

An eSTAR that does not reach a complete status is not accepted through the CDRH Portal. eSTAR submissions are not expected to undergo Refuse to Accept review, but a submission that fails technical screening may be placed on hold for up to 180 days, and is considered withdrawn if no replacement is received in that window.

Does eSTAR apply to combination products and biologics?

Yes. eSTAR covers submissions to both CDRH and CBER, and the mandatory scope for 510(k) and De Novo includes combination product submissions sent to either centre. PMA use across CDRH and CBER remains voluntary for now.

How should a Canadian firm prepare?

Map your existing technical file to the eSTAR structure, close the content gaps you find, confirm your FDA small business fee status, standardise your attachments, and decide whether to comment on the draft before 17 November 2026.

How MFLRC can help

MFLRC supports Canadian medical device manufacturers across the full regulatory lifecycle, from Canadian licensing to US and international market entry. For firms preparing a Class III device for the United States, we run PMA readiness gap assessments that map your technical file to the eSTAR structure, remediate the documentation the template will expect, and prepare the quality system records behind it. We also draft comments on FDA draft guidance on your behalf. Our work on the SOPs facilities most often get wrong and on supplier qualification programmes that survive inspection often feeds directly into a submission-ready file.

We pair submission strategy with quality system depth, including validation, CAPA and root cause investigations that survive inspection, so the file you submit is backed by systems that hold up after approval. If you are weighing a US Class III entry, an early readiness review is the highest-value step you can take.

Conclusion

The PMA eSTAR draft guidance is a signal, not a surprise. FDA has spent years moving submissions toward structured, guided templates, and the Premarket Approval application is the last major submission type to follow. For Canadian Class III device makers, the message is to prepare now: map your technical file to the template, close the gaps while the tool is still voluntary, and treat the 17 November 2026 comment window as a chance to shape the final version. The firms that map early will submit cleanly. The firms that wait for a mandate will map under pressure. Always confirm the current FDA guidance and eSTAR versions before you build a submission, because the templates and their requirements are updated over time.

Sources and references

• Federal Register, Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance; Availability (91 FR 59138, 18 September 2026)
• FDA, eSTAR Program
• FDA, Electronic Submission Template for Premarket Approval Applications (PMA) guidance page
• FDA, Premarket Approval (PMA)
• Regulations.gov, Docket FDA-2026-D-9429